All posts tagged
Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks
Celyad Starts a Third CAR-T Trial, in Metastatic Colorectal Cancer
Regenerating the Body With Stem Cells – Hype or Hope?
Celyad Reports Impressive Preliminary CAR-T Results in Solid Tumors
Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
Which EU Immuno-Oncology Company are you Cheering for?
What are the Best Countries to Recruit Biotech Talents in 2017?
CAR-T Competition Heats Up with a New IND Approval
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology
Infographic: What’s in Europe’s Immuno-oncology Pipeline?
10 Hot European Biotechs to Observe in 2017 🚀
Labiotech UG, All Rights Reserved -
Send this to a friend